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ABSTRACT

CRC is the second most common type of cancer in women and the third most
common type of cancer in men. It accounts for 9.7% of all cancers in terms of people
diagnosed. Measuring the real-time effect of chemotherapeutic drugs has been a major
obstacle in developing a tumor model mouse. Tracking the regression of cancer cells
after chemotherapy could be an effective way to resolve this issue. Therefore, cancer
cells expressing the constitutive luciferase reporter gene can be a potential solution.
The biggest advantage of the luciferase (Luc) reporter is that it is detectable at very low
concentrations in cell cultures, as well as in animal imaging. Here, we have analyzed
different transfection methods to find out the least toxic and most effective technique.
We have generated HCT116, a human colon carcinoma cell line, and MC38, a mouse
colon carcinoma cell line expressing the luciferase gene constitutively. The optimization
of four different transfection reagents was done. HCT116 and MC38 cells were finally
transfected with luciferase using Lipofectamine 3000 which had the highest efficiency.
Transfected cells were treated with G418 for two consecutive weeks. Single-cell
colonies were selected using determined antibiotic concentration and expanded. Stably
transfected cell lines were tested for luciferase expression using a luciferase assay.
Stability studies were performed for luciferase expression over 3 passages. HCT116Luc and MC38-Luc cells were grown on a 3D scaffold to form tumoroids that mimic in
vivo tumor microenvironment; tumoroids were tested for luciferase activity. HCT116-Luc

vi

and MC38-Luc cells were injected in mice subcutaneously and orthotopically to form
tumors and were tested after 7 days for luciferase activity post addition of D-luciferin
intraperitoneally. We have been able to generate stable Luciferase reporter HCT116
and MC38 colon cancer cell lines and bioluminescence Imaging was performed in mice
to study colon tumor progression. In conclusion, the luciferase reporter cell lines can be
used for studying the efficacy of chemotherapeutic drugs in colorectal tumor regression

vii

CHAPTER 1: INTRODUCTION

1.1 Colorectal Cancer

Colorectal cancer (CRC) is a heterogeneous disease that accounts for almost 10%
of cancer-related deaths occurring in the world, especially in western countries [1]. CRC
is the second most common type of cancer in women and the third most common type of
cancer in men, as it accounts for 9.7% of all the cancers in terms of people diagnosed [2,
3]. Between the age group of 20 and 49 years, the incidences of CRC have been
increasing since the past two decades.

1.2 Risk factors involved in CRC

Several studies have shown an increase in the number of incidences of CRC in
younger adults, with the highlighting cause being obesity and lack of activity [4]. The
differences in the diet and environment, along with genetics, have attributed to higher
incidences of CRC in Australia, New Zealand, Europe, and North America and lower
incidences in Asia and Africa [5]. CRC rates are 2-5 times higher in developed countries
as compared to the developing countries. The rates of incidences are very high in males
as compared to females [6].
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Lack of physical activity and family history with CRC remain to be the leading
factors for the cause of CRC [7]. Environmental and genetic factors also lead to CRC.
Lifestyle changes like quitting alcohol and tobacco can substantially decrease the
outcome of CRC. Also, changing the diet and including more vegetables, fibers, and
essential vitamins can prevent CRC. Some studies have also shown the risk of
consuming processed meat to be associated with CRC. Including fruit and antioxidants
in the diet also helps to reduce the causes of CRC. Keeping in check body fat distribution
and body mass index also decreases CRC risk [8, 9].
A very high risk of developing CRC is associated with specific genetic disorders,
which are mostly hereditary. Lynch syndrome accounts for 3% of the total CRC cases
and Familial Adenomatous Polyposis accounts for 1% of the total CRC cases. The genes
affected by these syndromes are MLH1, MLH2, MSH6, PMS2, APC, and EPCAM.
Attenuated Familial adenomatous polyposis is also an inherited CRC syndrome
that affects the APC gene and causes duodenal carcinomas. MYH-associated polyposis
is an inherited CRC syndrome that affects the MYH gene and is associated with
gastrointestinal carcinoma. Peutz-Jeghers syndrome affects the STK11 gene. Juvenile
polyposis alters the SMAD4 gene and is involved in CRC, pancreas, stomach and bowel
cancer. Cowden syndrome alters PTEN gene and affects the breast, thyroid, and
colorectum [10] Early screening of these inherited syndromes is difficult which results in
several cases between the age group of 25-50 years [10].
Studies have also shown that there is a significant increase in the risk of CRC with
a history of inflammatory bowel disease. The risk of CRC is also increased in people with
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a family history of CRC. The use of aspirin/NSAIDs also increases the risk of CRC[11].
Processed meat also has a substantial amount of effect on the occurrence of CRC [9].
The early detection of CRC can prevent the spread of disease and also prevent
the death of the patient [12]. CRC does not cause symptoms until the disease is advanced
to later stages, this makes it difficult to detect the disease and screen the patients. People
with a family history of inherited syndromes and CRC should always talk to the doctors
and screen for CRC [9, 12].
1.3 Screening of CRC

The tests used for the detection of CRC are divided into four categories based on the
method [3, 13].
❖ Endoscopic method
a. Colonoscopy – It is the most sensitive and standardized test for screening of
CRC. It is also used as a reference standard for other screening tests. It can
identify polyps and remove them in a single session. The frequency of
performing colonoscopy is every 10 years and it has been seen to reduce the
CRC rates by 77% [14]. One study has shown a reduction in mortality due to
colonoscopy screening[15]. The main disadvantages of colonoscopy are the
inconvenience and preparation of bowel for the actual screening [3, 13, 16].
b. Sigmoidoscopy – It is a technique that is used by the doctors to image inside
sigmoid of the colon with the help of a tube with light. It has a frequency rate of
every 5 years and is used to screen the lower half of the colon. It has shown a
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reduction in mortality rates in recent times and is more convenient compared
to colonoscopy [13, 17].
❖ Stool based tests
a. Guaiac-based fecal occult blood test (gFOBT) – It is used to find blood in the
feces, and stools. It must be done every year. It has shown some signs of a
reduction in mortality and can be performed at home, but it has limited ability
and needs to be followed up by colonoscopy [13].
b. Fecal immunochemical test (FIT) – It is highly sensitive, as it uses antibodies
to detect human hemoglobin in the stools. If the results of this test are positive,
it is followed up by colonoscopy [13, 18].
c. Fecal immunochemical test-DNA (FIT-DNA) – It is FDA approved and has a
screening frequency of 3-years. It uses multitarget stool DNA combined with
FIT, but is less specific than FIT [18].
❖ Radiography
a. Computed tomography (CT) colonography – It requires a skilled radiologist and
reduces bowel preparation as compared to colonoscopy. It is less sensitive
than colonoscopy, but has less risk involved and should still be followed up by
colonoscopy if positive [13, 19].
❖ Biomarkera. It is the first FDA approved serum test. It is the most convenient screening test
but has less sensitivity and specificity than colonoscopy [13, 20].
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1.4 Diagnosis
•

CT scan (CAT scan)

•

Magnetic resonance imaging (MRI)

•

Positron emission tomography scan (PET scan)

•

Chest X-ray

•

Lymph node biopsy

1.5 Symptoms of CRC [3, 21] –
•

Blood in the stool

•

Abdominal pain

•

Change in bowel movement

•

Anemia

•

Shortness of breath

•

Weight loss

•

Biliary obstruction

•

Impaired pulmonary function

•

Liver failure [3, 18]
1.6 Types of CRC

The types of CRC are based on the etiology and genetics of the disease [22].
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•

Sporadic colorectal carcinoma – 70% of the total CRC cases are based on this
type. It is most common in people older than 50 years of age. It is mainly caused
by environmental and dietary factors [3, 22, 23].

•

Inherited colorectal carcinomas – This type is caused by several inherited
syndromes. It includes the alteration of various genes. Lynch syndrome is the most
common syndrome that is prevalent in inherited CRC. It occurs due to a mutation
in one of the several mismatch repair (MMR) genes. MSH2 and MSH6 on
chromosome 2 and MLH1 on chromosome 3 are the genes found to be involved
in CRC. It accounts for 5% of that total CRC cases [22, 24].

•

Familial colorectal carcinoma – It accounts for 25% of the total CRC cases. The
pattern of this type is least known [22, 24].
CRC is also classified into two types, the most common one which accounts for
95% of the incidences is adenocarcinoma and the rare ones include squamous
cell carcinoma and lymphoma [3, 22].

1.7 Stages of CRC

The major cause of morbidity and mortality in men and women is adenocarcinoma
and the stages of CRC at diagnosis affect the mortality rates[25]. The most common
method used for staging CRC is the TNM (tumor/lymph node/metastasis) system by the
American Joint Committee on Cancer (AJCC) [25, 26].
•

Tumor (T) – Tumor has grown into the wall of the colon/rectum.
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•

Node (N) – Tumor has spread to the lymph nodes.

•

Metastasis (M) – Tumor has spread to other organs of the body[22].

Table no. 1 – CRC staging [25, 26]
AJCC stages

TNM

Tumor location

0

T1 N0 M0

Mucosa, the inner lining of the colon

I

T1/T2 N0 M0

Invaded layer of the colon/rectum

IIA

T3 N0 M0

Grown through walls of colon/rectum

IIB

T4a N0 M0

Grown through the layer of muscle to the lining

IIC

T4b N0 M0

Wall and around the colon

IIIA

T1 N1 M0

Spread to 1-3 lymph nodes

IIIB

T2/T3 N2 M0

Bowel walls and 1-3 lymph nodes

IIIC

T3/T4 N2 M0

4 or more lymph nodes

IV

anyT anyN M1

Spread to more than 1 part of the body

[22, 25, 26]
The survival percentage of patients with stage 1 CRC is 90%, stage 2 is 75-85%, stage
3 is 30-40% and of stage 4 is less than 5% [22]

1.8 Treatment for CRC

The treatment of CRC is mainly divided into three categories – surgical treatment,
radiation therapy, and treatment with small molecules.
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➢ Surgical treatment
o Laparoscopy – It uses scopes and surgical tools inserted into the abdomen. It
is a conventional method to remove the tumor. It requires trained surgeons [27].
o Robotic surgery – It uses robots and has short- and long-term outcomes. It is
safer than conventional surgery [27].
o Colostomy – When a stoma is made outside the body for waste to pass out,
the procedure is called a colostomy. This is done for healing the lower part of
the colon. This is followed by chemotherapy or radiation therapy [28].
o Radiofrequency ablation – In this method, high energy radiofrequency is used.
Generally, a tiny electrode is inserted into the body and used to kill the cancer
cells [28].
o Cryotherapy – In this therapy, the tumor is frozen and destroyed [28].
➢ Radiation therapy
o It uses high energy X-rays and other types of radiations to kill cancer cells and
boost cancer treatment. This therapy is used in combination with chemotherapy
due to the reoccurrence of tumors from the original site [28].
➢ Treatment using small molecules
o Chemotherapy – Chemotherapy is the use of drugs to kill the cancer cells and
prevent them from growing. The anti-cancer drugs can be taken orally or
injected into the bloodstream through the vein or muscle. The most common
anticancer drugs used for CRC are fluorouracil 5-FU, Irinotecan, and FOLFOX
therapy (folinic acid, fluorouracil, and oxaliplatin) [28].
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o Targeted therapy – This type of treatment uses drugs to target specific proteins.
It includes the use of antibodies, VEGF inhibitors, EGFR inhibitors. Some of
the examples are Bevacizumab, Cetuximab, and panitumumab, etc [28].
o Immunotherapy – This therapy uses the human immune system to fight cancer.
It uses immune checkpoint inhibitors to kill cancer cells. Some of the examples
of this therapy are Pembrolizumab, Nivolumab, a combination of nivolumab and
ipilimumab, etc. [28].

1.9 Using reporter genes to test the efficacy of CRC treatment

Reporter genes are genes that encode detectable proteins. These genes contain
a promoter that drives the expression of the proteins. Reporter genes are widely used to
study cell biology and study gene expression in animals [29]. Reporter genes are
classified into two categories non-fluorescent proteins and fluorescent proteins. Nonfluorescent proteins include chloramphenicol acetyltransferase and the lacZ gene. The
most commonly used fluorescent proteins are green fluorescent protein (GFP) and red
fluorescent protein (RFP). Other fluorescent proteins include enhanced yellow (EYFP),
enhanced cyan (ECFP), enhanced blue (EBFP), and mCherry [30]. Luminescent
reporters have been used in the cell-based reporter assays. They have a lot of benefits
like shorter assay time, early detection, and higher sensitivity. They also eliminate the
problems caused by fluorescence compounds [31-33]. The biggest advantage of
luciferase (Luc) protein is that it is detectable at very low concentrations in the cell
cultures, animal imaging, deep tissue imaging, and the time required to detect the signal
9

is also less [34]. Firefly luciferase is a light emitting enzyme that is responsible for
bioluminescence. The light produced Is because of the excitation of oxyluciferin which is
formed after the reaction occurring between the luciferase enzyme and the substrate Dluciferin. Firefly is a polypeptide that can be cloned into vectors for its use in gene delivery.
Luciferase expression vectors can be used in the generation of stable clone and to track
tumor cells [35]
Reporter expressing cells are the cells that incorporate foreign reporter proteins,
which can then be used in a number of in-vivo and in-vitro applications [31]. The stable
luciferase reporter cells respond rapidly to the endotoxins and the non-endotoxin
pyrogens and can be used to develop an effective detection method [36]. It is also found
that only a few cells are required to develop a tumor in the mice and the progression of
the tumor can be monitored right after the cells are implanted [37]. Immunogenicity of
luciferase compromises the metastatic activity of the reporter expressing tumor cells [38].
Luciferase activity does not inhibit the tumor growth in the mouse model and also does
not alter the tumor activity in cells [39].
Transgenic mice with a specific reporter gene can be obtained by inserting the
gene of interest in the fertilized egg. Transgenic mice enable quick assessment of specific
organs and tissues. It can also be used for toxicologic analysis, to study genotoxicity, and
to study stem cell therapies [29].
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1.10 Current Imaging techniques

The noninvasive imaging of tumors in murine mice model has always been a
challenge; significant advances have been made in imaging the tumor in recent times.
Some of the methods used to image tumors in mice are included in the table below.
Table no. 2 – Current imaging techniques
Sr
No.
1

2

Imaging Modality
Magnetic

resonance

Disadvantages

High spatial resolution; provides both

Low sensitivity, long acquisition

imaging (MRI) scan

anatomical and functional details

and image process times

Positron

High sensitivity; provides

Required to generate

a quantitative measure of tumor

short-lived radioisotopes; low

cell metabolism

resolution; Increase noise

Radioisotopes

Between 10- and 100-fold less

computerized

have longer half-lives than those

sensitive than PET

tomography

used in PET

emission

tomography (PET) scan

3

Advantages

Single-photon

emission

(SPECT) scan
4

5

6

CT scan (X-rays)

Fluorescence Imaging

Intra-vital microscopy

Morphological detection of

Relatively poor soft-tissue

tumors and metastases

contrast

Multiple reporter wavelengths

Attenuation with increased tissue

enables multiplex imaging

depth; autofluorescence

Tracking of labeled cell populations

limited

to

relatively

superficial

tissues
7

Ultrasound

Images morphology and physiology of

Limited ability to image through

tissue relatively close to the surface of

bone or lungs

the mouse in real-time
8

Bioluminescence

High sensitivity; provides relatively

Imaging (BLI)

measure cell viability or cell
function; high throughput, versatility

[40]
11

Low anatomic resolution

1.11 Bioluminescence Imaging

In certain ecological systems, certain living organisms have been given an
advantage with bioluminescence. The ability to emit light in darkness in certain species
has been observed. Bioluminescence is a result of a chemical reaction which involved
luciferase enzyme. There are two main types of systems- the Coelenterazine dependent
system which includes Rennilla luciferase, gaussia luciferase, and nanoluc luciferase.
The second type of system is the D-luciferin dependent system which includes Firefly
luciferase and click beetle luciferase [41].
Tumor progression in animal model possesses a lot of limitations. Most of the
studies lead to the sacrifice of several animals. Some of the noninvasive techniques that
are used to overcome these limitations are ultrasonography, computerized tomography,
positron emission tomography, single-photon emission computed tomography and
magnetic resonance imaging. Bioluminescence and fluorescence imaging have been
used for in vivo monitoring and imaging of gene expression [42]. Bioluminescence
provides an opportunity for in vivo imaging. Bioluminescence has been used to track the
cells and the gene expression in the animals. The oxidation of small substrates called Dluciferin occurs by which the luciferase enzyme catalyzes the oxygen and converts
luciferin to oxyluciferin and emits light [39]. It has a half-life of approximately 3 hours. This
enables sensitive imaging in the animals [43]. Bioluminescence imaging is used to
monitor tumor progression and has already been successfully applied to breast, colon,
and lung cancer [44-46].
12

1.12 Advantages of Bioluminescence Imaging

1. Highly sensitive
1. Quick and easy to perform
2. Relative low cost
3. Long term imaging applications with no risk of phototoxicity
4. Detectable over low to no background noise
5. No need to sacrifice animals
6. Cancer stem cell imaging at high resolution
7. Micro-metastasis imaging capabilities

1.13 Transfection

Transfection is a method used to deliberately introduce foreign nucleic acid
into the cell. It is introduced into the cell to study gene function. The transfected nucleic
acid expresses a specific gene/genes with the help of a promoter in the cell. There are
two types of transfection –
a) Transient transfection
b) Stable transfection
Transient transfection involves the introduction of a plasmid into the nucleus without
integration into the genome. Whereas, in a stable transfection, a foreign plasmid is
integrated into the genome. Once transient transfection is obtained the transfected cells
13

are selected using selected antibiotic concentration which is obtained by performing an
antibiotic kill curve. The antibiotic will kill the non-transfected cells and leave the
transfected cells unharmed due to the expression of antibiotic resistance genes. From the
selected transfected cells single cell colonies can be grown by limiting dilution to establish
a stably transfected cell line [47].

Figure 1: Stable transfection vs Transient Transfection

The methods used to transfect mammalian cells are mainly divided into three categoriesa) Biological transfection - These methods use viral vectors to transfect the cells.
The advantages of this method are that it has high efficiency and it is easy to
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use. Its disadvantage is that it is hazardous to personnel working with it and
also can cause mutagenesis [48].
b) Chemical transfection - Includes a cationic polymer, calcium phosphate, and
cationic lipid. It has high efficiency and is easy to use. The transfection
efficiency is cell line dependent. Chemical transfection is toxic to cells at high
concentrations. Liposome mediated transfection is also widely used to transfect
mammalian cells. In this method liposomes made of phospholipids are
complexed with the DNA which are able to enter through the heparin
proteoglycan layer of the cell and deliver the plasmid to the nucleus [49].
c) Physical transfection – Includes electroporation, biolistic gene delivery,
sonoporation, and nanoparticle-mediated transfection. It may require special
instruments. Skilled personnel required [50].

Figure 2: Liposome mediated transfection.
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Hypothesis

Measuring the real-time effect of chemotherapeutic drugs has been a major obstacle in
treating a tumor in the mouse model. Tracking the regression of cancer cells after
chemotherapy could be an effective way to resolve this issue. The development of an
Imaging technique for mouse tumor model will enable specific, highly sensitive and
quantitative measurement of a wide range of tumor-based parameters that also mimics
the natural environment of tumor progression in colon cancer. The first aim of this project
is to optimize the conditions and parameters for stable transfection of HCT116 and MC38
colon cancer cell lines with Luciferase plasmid. The second aim is to generate stably
transfected luciferase reporter cell lines and test their stability. The third aim is to test
HCT116-Luc and MC38-Luc cells in an orthotopic tumor model in mice.
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CHAPTER 2: MATERIALS AND METHODS

2.1.

Materials:

HCT116 (human colorectal carcinoma) and MC38 (mouse colon carcinoma) were
acquired from ATCC. MCOYS 5A media (SH30200.01) with 10% Fetal Bovine Serum
(FBS) and 1% Penicillin/Streptomycin (P/S) (SV30010) which were purchased from
Gibco, USA. Tissue culture plates and dishes were purchased from Thermofisher, USA.
Luciferase plasmid (18964) was purchased from Addgene, USA. Geneticin antibiotic
(SV30069.01) 100mg/ml was purchased from Hyclone, USA. Steady-Glo Luciferase
assay kit (E2510) was purchased from Promega Corporation. Luminescence was
measured using a Synergy plate reader by BioTek. Microscopy was done using a
Keyence microscope. Lipofectamine 3000 (L3000015) was purchased from Invitrogen.
Mirus TransIT-LT1 and Mirus TransIT-X2 (MIR 2304) (MIR6003) were purchased from
Mirus. Green Fluorescent Protein (GFP) (11150) was purchased from Addgene.
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2.2. Methods:

2.2.1 Cell culture
HCT116 (human colorectal carcinoma) cells were cultured in a 100 mm petri dish
using Gibco McCoys’s 5A media with 10% Fetal Bovine Serum (FBS) and 1%
Penicillin/Streptomycin (P/S). MC38 (mouse colon carcinoma) cells were cultured in a
100 mm petri dish using Dulbecco's Modified Eagle Medium (DMEM) with 10% FBS, 1%
P/S, 1% sodium pyruvate and 1% Non-essential amino acids. The cells were incubated
in a humidifier at 37ºC and 5% CO2. Both the cell cultures were passaged when reached
80-90% confluency. The cells after reaching 80% confluency were washed with 10 ml 1X
PBS in a petri dish. After removing the PBS solution, 3 mL Trypsin EDTA was added to
the petri dish containing cells and the dish was swirled and incubated for 30 seconds in
the incubator for the cells to detach from the surface of the dish. After the cells were
detached from the plate, 5 ml of fresh media was added to de-trypsinize the cells. The
cells were then collected in a 15 ml tube and spun down in a table-top centrifuge at 1250
rpm for 3 minutes. The supernatant was discarded after centrifugation and the cell pellet
was resuspended in 5 ml of fresh media. From 5 ml of cell suspension, 100 µl of cell
suspension was suspended in fresh 10 ml media in a 15 ml tube and then plated in a Petri
plate. For experiments, cells were counted using a hematocytometer. 10 µl of cell
suspension was mixed with 90 µl of Trypan blue dye and from this solution, 10 µl was
placed on a hematocytometer. Live cells in all 4 quadrants were calculated and divided
by 4, then multiplied by 105 to get the number of cells in 1 ml of suspension. For different
18

experiments, 96, 48, 24, 12 and 6 well plates were used and cells were plated to a
confluency of 60-70%. For cryopreservation of cells, 2 million cells were pelleted and
suspended in 1 ml of media with 5% DMSO and transferred to 2 ml cryovials that slowly
froze overnight at -80º C and then stored at -150º C.

2.2.2 Tumoroid culture

Polymeric nanofiber scaffolds were used to form tumoroids. The scaffolds were
placed in a 96 well plate using forceps and sterilized using ethanol (3 times) and 1X PBS
wash (2 times) and then exposed to UV rays for 45 minutes. The PBS was replaced with
100 µl fresh media and incubated in an incubator for 30 minutes. Cells were counted and
plated on the scaffold with 50 µl of media to stabilize the cells on scaffold and placed in
the incubator overnight at 37ºC and 5% CO2. The next day 150 µl of fresh media was
added to each well. Tumorid formation was assessed from day 3-6 using a fluorescent
microscope (EVOS). Nuclear staining was done using 12 µl of Nuc Blue dye
(ThermoFisher Scientific) and incubation of 45 mins [51].

2.2.3 Cell viability assay

CellTiter-Glo® (CTG) luminescent Cell Viability (Promega G7572) assay was used
to check the cytotoxicity in cells. 100 µl CTG reagent was added to each well of 96 well
plate containing cells in 100 µl of media. The plate was covered with aluminum foil and
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placed on the shaker for 15 minutes. After 15 minutes 100 µl of the solution was taken
and added to a 96 well white plate and luminescence was measured using the plate
reader Synergy by BioTek.

2.2.4 DNA Isolation

Figure 3: DNA Isolation using a miniprep kit

The luciferase-pcDNA3/E. coli cells were streaked on a Lauria (LB) broth agar
plate (37 LB/L) containing ampicillin (100 µg/ml). Bacterial culture was grown overnight
by inoculating the bacteria in LB media. The inoculated plate was incubated overnight at
37ºC. Individual colonies were picked using a sterile tip and transferred to 50 ml LB media
(30g/L) containing 100 µg/ml ampicillin. Luciferase plasmid was isolated using Qiagen’s
Mini-prep DNA isolation kit. The bacterial pellet was formed by centrifugation at 8000 rpm
for 5 minutes at room temperature. The bacterial pellet was resuspended in 250 ul P1
buffer and was transferred to a microcentrifuge tube. 250 ul of buffer P2 was added and
mixed by inverting the tube 5-6 times until the solution becomes blue. 350 ul of buffer N3
was added and mixed until the solution becomes colorless. The solution was centrifuged
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for 10 mins at 13000 RPM. The supernatant was applied to the QIAprep spin column. The
column was centrifuged for 60 secs. The column was washed with buffer PB and then
centrifuged for 60 secs. DNA was eluted by adding 50 ul of buffer EB and centrifuged
into a clean tube. The concentration of DNA was measured in the plate reader Synergy
by BioTek [52].

2.2.5 Agarose Gel Electrophoresis

Agarose gel electrophoresis was performed to confirm the luciferase plasmid after
isolation. 0.8% gel was used to run two different concentrations of plasmids. Ethidium
bromide was used as the dye for imaging and a 10Kb ladder was used.

2.2.6 Antibiotic kill curve

HCT116 and MC38 cells (2,000/well) were plated in a 48 well tissue culture plate.
After reaching confluency of 70%, the cells were treated in triplicates with antibiotic
Neomycin (G418) at concentrations of 0, 100, 200, 300, 400, 500, 600, 700, 800, 900,
1000, 1200, 1500 μg/ml in increasing order and three control wells with no G418. The
media with Neomycin was replaced every 2-3 days and examined regularly for visual
cytotoxicity. Visual cytotoxicity was assessed and selection antibiotic concentration which
killed more than 50% of the cells was determined after 7 days. CTG assay was performed
following the procedure as discussed above to develop an antibiotic kill curve [53].
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Figure 4: Antibiotic kill curve. To determine the concentration of selection antibiotic

2.2.7 Transfection of Cells

In a 24 well tissue culture treated plate 1 x 105 cells were seeded. Seeded cells
were allowed to be 70% confluent at transfection. 0.75 µl of Lipofectamine® 3000 was
diluted in 25 µl of Opti-Mem media in a 1.5 ml Eppendorf tube and mixed well. 1 µg of
DNA was diluted in 50 µl of Opti-Mem media and then 2 µl of P3000 reagent was added
to the DNA mixture. 25 µl of the diluted DNA was added to the diluted Lipofectamine®
3000 solution. The mixture was incubated for 15 minutes at room temperature. The DNAlipid complex was added to the cells. The media with transfection reagent was replaced
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with fresh media after 6 hours. The cells were incubated at 37ºC and 5% CO2 for 48 hours.
Transfected cells were analyzed after 48 hours for protein expression.

Figure 5: Transfection of cells using Lipofectamine 3000 reagent

2.2.7 Optimization of transfection reagents.

The optimization of four different transfecting agents was performed. Cells were
seeded in 24 well tissue culture treated plate at a seeding density of 1 x 105 cells per well.
Cells were allowed to grow and reach a confluency of 80%. Cells were transfected with
Green Fluorescent Protein (GFP) with a concentration of 500 ng. GenJet™, Mirus TransIT® LT1, Mirus Trans-IT® X2, and Lipofectamine® 3000 transfecting reagents were used
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as shown in figure no. 7. Transfection was performed by following the procedure
discussed above. After 48 hours the cells were examined for fluorescence protein
expression and images were taken in the Keyence microscope. Transfection efficiency
was first determined visually. Transfection efficiency was calculated by counting the
number of transfected cells and nontransfected cells in ImageJ software.

Figure 6: Optimization of transfecting reagents using four different transfecting reagents

2.2.8 Generation of Stable transfection.

HCT116 and MC38 cells were plated in 24 well culture treated plate and grown to
a confluency of 70-80%. Cells were transfected using Lipofectamine® 3000. The media
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was changed after 6 hours to avoid toxicity. Post 48 hours of transfection, the cells were
treated with selection antibiotic (G418). As per figure no. 7, positive and negative control
were maintained. The positive control contained no plasmid but G418. The negative
control contained no plasmid and no G418. Media with selection antibiotic was replaced
every 2-3 days for 10 days. After the cells in the positive control were dead and the
transfected cells became confluent, the transfected cells were transferred to a 60 mm
tissue culture plate. The cells were then plated in 96 well plates at 1 cell per well to form
colonies from an individual cell. 10 cells per well were obtained by performing limiting
dilution which is as follows – a 10 ml cell suspension containing 1000 cells per ml was
formed. From this cell suspension, 1 ml suspension was added to a 15 ml tube containing
9 ml of fresh media to form a cell suspension of 100 cells per ml. From this again by
further dilution a cell suspension was obtained of 10 cells per ml as shown in figure no.
7. The cells were then plated in a 96 well plate. The cells were allowed to form colonies
for 1-2 weeks. Single-cell colonies were identified. The clones were checked for luciferase
activity. Once the verification of clones was done, the clones were expanded to 6 well
plates and then to tissue culture flasks. Early passages of the clones were frozen down
to stocks for use in future experiments. 20 vials with early passage of each clone were
frozen down to ensure enough stock [54].
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Figure 7: Generation of stable transfection by forming single-cell colonies using limiting dilution.

2.2.9 Luciferase Assay

Cells were detached by trypsinizing using Gibco Trypsin EDTA . 1 X 105 cells were taken
into 1.5 ml Eppendorf tube. Cells were lysed by adding 100 μl lysis buffer. This mixture
was then sonicated at an amplitude of 28 for 6 sec. Then the sonicated mixture was
centrifuged at 10,000 rpm for 15 minutes. The supernatant was collected and added to a
white 96 well plate. Steady-Glo assay reagent was added at a ratio of 1:1 (media: assay
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reagent) and luminescence was measured in the plate reader Synergy by BioTek as
shown in figure no. 8.

Figure 8: Luciferase assay

2.2.10 In vivo experiment

5-6 weeks old Athymic nude-nude mouse was injected with 3 x 106 HCT116-Luc
cells on the left and right flank and 2 x 106 HCT116-Luc cells were injected into the cecum
by performing orthotopic survival surgery. 5-6 weeks old C57BL/6 mouse was injected
with 1 x 106 MC38-Luc cells on the right flank and 1 x 106 MC38-Luc cells were injected
into the cecum by performing orthotopic survival surgery. Intraperitoneal injection
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(150mg/kg) of the D-luciferin substrate was started 7 days after tumor cell injection and
was given once every week. Bioluminescence was tested using the PerkinElmer In-Vivo
Imaging system. All animal work was approved by and performed following the policies
of the University of South Florida Institutional Animal Care and Use Committee [51].

Figure 9: In vivo Bioluminescence Imaging of HCT116-Luc and MC38-Luc in a subcutaneous and orthotopic
tumor model.

2.2.11 Statistical Analysis
All the quantitative data were analyzed through mean ±S.E.M. A p value < 0.05
was considered statistically significant.
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CHAPTER 3: RESULTS AND DISCUSSIONS

3.1 Luciferase plasmid

Luciferase plasmid was isolated and confirmed using agarose gel electrophoresis.
The nicked/linear band was seen on the gel around 7000 base pair (bp) and supercoiled
DNA was seen between 2500 and 3000 bp. This confirms that the plasmid isolated from
E. coli bacterial colonies encoded luciferase gene obtained from the Add gene as it
corresponds to the 7041 bp value provided by the Add gene (Figure 10).

3.2 Lipofectamine 3000 is an effective transfection reagent for HCT116 and
MC38 cells.

Thermofisher Scientific has shown the efficiency of Lipofectamine 3000 as
compared to Lipofectamine 2000 and FuGENE HD in HEK293 T cells. They have also
shown that with lipofectamine 3000, lower concentration of the lipid can be used and
still achieve the same amount of transfection efficiency which lowers the toxicity of the
lipid in the cells. Azman Taz et al. have also shown that using a lower ratio of DNA to
lipid gives the best transfection efficiency. Considering all these parameters for
optimization, we performed an optimization using GenJet, Mirus TransIT -LT1, Mirus
TransIT -X2 and Lipofectamine 3000 transfection reagents with GFP plasmid. We found
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that Lipofectamine 3000 performed better and gave the highest transfection efficiency
as compared to others for both HCT116 and MC38 cells, as shown in Fig no. 11. The
transfection efficiency for HCT116 cells using Lipofectamine 3000 was found to be
27.5% and MC38 cells was found to be 24%. Lipofectamine 3000 was seen to
significantly increase the transfection efficiency in HCT116 and MC38 cells. The same
studies were then performed using luciferase plasmid and gave similar results. This
confirms that Lipofectamine 3000 gives the highest transfection efficiency in HCT116
and MC38 cells as shown in Fig no. 11.

Figure 10: A) Luciferase plasmid map, B) Luciferase plasmid crystal structure, C) Luciferase plasmid
agarose gel electrophoresis

.
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Figure 11: A-B) Optimization of transfection efficiency: A) HCT116, B) MC38, CD) quantification of transfection efficiency: C) HCT116, D) MC38, E-F) Transfection
optimization with Luc, E) HCT116, F) MC38.
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3.3 Determination of selection antibiotic concentration (Neomycin) for
HCT116 and MC38 cells.

Antibiotic kill curve was performed to find out the concentration of selection
antibiotic in HCT116 and MC38 cells that will be used in the generation of stable
transfection of HCT116 and MC38 cells. The selected antibiotic concentration of
Neomycin, by visual toxicity under the microscope, for HCT116 cells was found to be 400
µg/ml and MC38 cells was found to be 600 µg/ml. As indicated in Fig no. 12 (A, B) the kill
curve obtained after performing CTG assay of the treated cells and control also confirms
the selection antibiotic concentration of Neomycin for HCT116 cells to be 400 µg/ml and
MC38 cells to be 600 µg/ml as shown in Fig no. 12.

3.4 Stable transfected HCT116-Luc and MC38-Luc cells.

The HCT116 and MC38 cells were successfully transfected with luciferase plasmid
using Lipofectamine 3000 transfecting reagent. After the selection of transfected cells,
single-cell colonies were successfully formed in a 96 well plate. 17 clones for HCT116Luc were tested for luciferase activity and the luciferase activity of 17 clones can be seen
in Fig no. 13 (A, B). 12 clones of MC38-Luc were tested for luciferase activity and the
luciferase activity of 12 clones can be seen in Fig no. 13 (C, D).
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Figure 12: A-B) Selection antibiotic concentration for A) HCT116, B) MC38, C-D) Antibiotic
kill curve C) HCT116, D) MC38.
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3.5 Stability studies of HCT116-Luc and MC38-Luc cells

According to the luciferase activity of clones #1-17 of HCT116-Luc cells from
the plate reader and In vivo imaging system (IVIS), three clones (#9, #16 and #17)
with the highest luciferase activity were selected. Stability studies of HCT116-Luc

Figure 13: A) Luciferase activity and radiance of HCT116-LUC clones in the plate reader, B)
Luciferase activity and radiance of HCT116-Luc clones in IVIS, C) Luciferase activity of MC38-Luc
clones in the plate reader, D) Luciferase activity of MC38-Luc clones in IVIS.
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clones #9, #16 and #17 were performed by testing the luciferase activity of each
selected clone after every passage for a total of 3 passages as shown in Fig no. 14.

Figure 14: A) Luciferase activity of HCT116-Luc over 3 passages, B) Luciferase activity of MC38-Luc over
3 passages, C) Luciferase expression of HCT116-Luc clone 9 over 3 passages in IVIS, D) Luciferase
expression of HCT116-Luc clone 9 for different cell counts, E) HCT116-Luc signal intensity over 40 mins,
F) Luciferase expression of MC38-Luc clones 1,2 and 3 over 3 passages in IVIS, G) Luciferase
expression of MC38-Luc clones 1,2 and 3 for different cell counts, H) MC38-Luc signal intensity over 40
mins.
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After testing the luciferase activity in the plate reader, there was a decrease in the
luciferase activity of clone #16 and clone #17 after every passage. Clone #9 was seen
to have stable luciferase activity after each passage. The stability of clone #9 over the
three passages was confirmed with the luciferase activity in the IVIS. The luciferase
activity of clone #9 for the number of cells versus the expression was checked in the
IVIS and an increase in luciferase expression was seen with an increase in the number
of cells as shown in Fig no. 14 (A, C, D). The luciferase signal stability of HCT116-Luc
cells was also tested throughout 40 minutes and the signal was found was to be stable
with an expression peak at 20 minutes as shown in Fig no. 14 (E). Similarly, the
luciferase activity of clones #1-12 of MC38-Luc cells from plate reader and IVIS was
tested and clones #1, #2, #3 and #10 were found to have the highest luciferase activity.
The stability of these clones was tested over three passages and there was a decrease
in the luciferase expression of clone #10. The stability of MC38-Luc clones #1, #2 and
#3 was tested in the IVIS and the luciferase activity of the three clones was confirmed to
be stable. The luciferase expression for MC38-Luc clone #1 cells was found to increase
with the increase in the number of cells as shown in Fig no. 14 (B, F, G). The luciferase
signal stability of MC38-Luc cells was also tested throughout 40 minutes and the signal
was found to be stable with an expression peak at 20 minutes as shown in Fig no. 14
(H).
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3.6 HCT116-Luc and MC38-Luc cells for tumoroids on a 3D scaffold.

HCT116-Luc clone #9 formed tumoroids on a scaffold on day 4 shown in Fig no.
15. The luciferase expression of HCT116-Luc clone #9 was checked in monolayer versus
scaffold. An increase in expression from the HCT116-Luc tumoroid was compared to the

Figure 15: A) HCT116-Luc tumoroids on scaffold (4x), B) HCT116-Luc
tumoroids on the scaffold (10x), C-D) HCT116-Luc luciferase expression
in monolayer vs scaffold, E) MC38-Luc tumoroids on the scaffold (4x), F)
MC38-Luc tumoroids on the scaffold (10x), G-H) MC38- Luc luciferase
expression in monolayer vs scaffold.
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monolayer of HCT116-Luc as shown in Fig no. 15. The average signal intensity of
HCT116-Luc on the scaffold was seen to increase (>2 fold) significantly in comparison to
the monolayer. Tumoroid formation was seen for three selected clones of MC38-Luc on
the scaffold on day 4. The tumoroids on the three clones were checked for luciferase
expression and compared to the monolayer. The MC38-Luc tumoroids were found to
have a significant increase (>2 fold) in luciferase expression compared to the monolayer.

3.7 HCT116-Luc and MC38-Luc show in vivo tumor progression in
subcutaneous and orthotopic tumor model after performing
bioluminescence imaging.

The HCT116-Luc tumors in a subcutaneous and orthotopic xenograft model were
imaged in the IVIS on days 7, 14 and 21. The HCT116-Luc cells were seen to form the
tumor in both subcutaneous and orthotopic models as seen in Fig no. 16 (A, C). Tumor
progression in the subcutaneous model can be seen from day 7 to day 21 with an increase
in the size of the tumor which is also confirmed with the average radiance of the tumor on
days 7, 14 and 21. The orthotopic tumor model showed tumor formation and could be
imaged by bioluminescence imaging on day 21. Similarly, the MC38-Luc tumor was
formed in both the subcutaneous and orthotopic syngeneic model. Both models were
seen to form a tumor on day 7 as shown in Fig no. 16 (B, D).
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Figure 16: A) HCT116 tumor growth in subcutaneous tumor model BLI, B) MC38-Luc tumor development
BLI in subcutaneous tumor model, C) HCT116-Luc tumor development BLI in orthotopic tumor model, D)
MC38-Luc tumor development BLI in an orthotopic tumor model.
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CHAPTER 4: DISCUSSION AND CONCLUSION

Imaging the tumor progression and tracking the tumor regression after chemotherapy has
always been a challenge to demonstrate the effect of chemotherapeutic drugs on the
tumor in mouse models. Fluorescence imaging has a lot of disadvantages like
autofluorescence from other tissues of the body [32]. The current imaging modalities had
a lot of drawbacks, which lead to oncology drugs being amongst the least in terms of
translation from phase 1 to phase 2 clinical trials[40]. Here, we demonstrated a tumor
model for CRC to track the progression of the tumor in mice. Mimicking the tumor
environment in humans, this tumor model also has the capabilities of imaging the tumor
progression. Transfection efficiency of HCT116 and MC38 cells were optimized with GFP
plasmid. Lipofectamine 3000 was found to have high transfection efficiency in HCT116
and MC38 cells. HCT116 and MC38 cells were stably transfected with firefly Luciferase
and three of the best clones each were selected. Stability studies of the three HCT116Luc and MC38 clones were performed to ensure stable luciferase activity of the clones.
The most stable HCT116-Luc and MC38-Luc Clones were injected in mice
subcutaneously and orthotopically to track tumor progression. Bioluminescence imaging
was successfully performed, and tumor growth was tracked every week. In conclusion,
here we show luciferase reporter CRC cell lines can be a potential solution to overcome
the drawbacks of currently employed imaging techniques for tracking the tumor
progression in mice.
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